Dose finding studies with imidapril--a new ACE inhibitor

Area of Science:

• Cardiology
• Pharmacology

Background:

• Essential hypertension is a prevalent cardiovascular condition requiring effective treatment.
• Angiotensin-Converting Enzyme (ACE) inhibitors are a key class of antihypertensive medications.

Purpose of the Study:

• To investigate the antihypertensive effects of ascending doses of imidapril, a novel ACE inhibitor.
• To determine the optimal and safe dosage range for imidapril in patients with mild to moderate essential hypertension.

Main Methods:

• Prospective, placebo-controlled studies involving patients with essential hypertension (baseline SDBP 95-115 mm Hg).
• Patients received escalating doses of imidapril (2.5-40 mg) or placebo over 2 or 4 weeks.
• Sitting diastolic blood pressure (SDBP) was the primary efficacy endpoint.

Main Results:

• Imidapril at 10 mg, 20 mg, and 40 mg significantly reduced SDBP compared to placebo.
• No significant differences in efficacy were observed between the 10 mg, 20 mg, and 40 mg doses.
• The 2.5 mg dose showed no significant effect, while the 5 mg dose had an intermediate effect.
• Adverse event incidence was similar between imidapril and placebo groups, indicating a favorable safety profile.

Conclusions:

• Imidapril demonstrates significant antihypertensive efficacy in patients with mild to moderate essential hypertension.
• A dose of 10 mg imidapril appears sufficient to achieve maximal ACE inhibition and blood pressure reduction in most patients.
• Imidapril is well-tolerated, with an adverse event profile comparable to placebo.